Open AccessThe Prevalence and clinical characteristics of primary S jogren's syndrome patients with lung cancer: An analysis of ten cases in C hina and literature review
Author(s) -
Xu Yan,
Fei Yunyun,
Zhong Wei,
Zhang Li,
Zhao Jing,
Li Longyun,
Wang Mengzhao
Publication year - 2015
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12216
Subject(s) - medicine , lung cancer , adenocarcinoma , lung , incidence (geometry) , cancer , gastroenterology , metastasis , oncology , physics , optics
Background A retrospective analysis of clinical data from primary S jogren's syndrome ( pSS ) patients with lung cancer was conducted in order to guide further clinical work. Methods From J anuary 1993 to D ecember 2010, 10 pSS patients with lung cancer were hospitalized at the P eking U nion M edical C ollege H ospital. One hundred and three p SS patients were recruited as the controls. Patients' clinical data was retrospectively analyzed. Result The incidence rate of lung cancer in pSS patients was 0.477%. The duration from diagnosis of pSS to lung cancer in the 10 patients was 0.92∼42 years. The pSS patients with lung cancer were significantly older than those without lung cancer (60.8 ± 8.9 vs. 44.9 ± 12.1, P < 0.001). Eight of the pSS patients with lung cancer (80%) were female nonsmokers; five pSS patients with lung cancer (50%) had lung involvement, exhibiting diffuse parenchymal lung disease. Adenocarcinoma was the most common pathological type of lung cancer (90%). Tumor node metastasis staging of lung cancer included: four cases of Ib (40%), one case of IIIb (10%), four cases of IV (40%) and one case undetermined (10%). Conclusion The incidence rate of lung cancer in pSS patients was higher with respect to the normal population. Physicians should closely observe lung cancer incidence during the pSS follow‐up period. Adenocarcinoma was the most frequently seen lung cancer pathology in pSS patients. Clinical stages and individualized treatment for pSS patients with lung cancer should be carefully determined.